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Background
In vivo delivery of HIV antigens within a-DEC 205 anti-
bodies to maturing dendritic cells (DCs) in combination
with maturation stimuli is a potential new vaccine plat-
form. This phase-I study evaluates the safety and immu-
nogenicity of DEC-targeting of HIV gag p24 in
combination with poly ICLC in healthy volunteers.
Methods
45 volunteers aged 18-60 were enrolled. 9 volunteers per
dosage group (low: 0.3mg; mid: 1.0mg; high: 3.0mg)
received a-DEC205-HIVp24 mAb plus a fixed dose of
poly ICLC s.c., 3 volunteers received poly ICLC only,
and 3 volunteers received saline, in a randomized dou-
ble-blinded dose escalation design. Volunteers were vac-
cinated at weeks 0, 4, 12 and followed for 12 months.
Results
Study remains blinded. Transient local and systemic
reactogenicity occurred, without vaccine-related serious
adverse events to date. Gag p24-specific IgG was
induced in 9/15 (60%, 9 received vaccine plus adjuvant)
volunteers in both low dose and mid dose groups at
weeks 4, 8, 12, and 16. IgG titers were higher in the mid
dose group and responses persisted for at least 6
months after last low dose immunization. Gag-specific
CD4+ T cells were also detected following immuniza-
tions. IL-2 and TNF-a were the predominant cytokines.
For CD4+ cells producing IL-2 or TNF-a, the response
rates ranged from 33 to 46% (5-7/15 volunteers,
9 received vaccine plus adjuvant) and 8 to 40% (1-6/15
volunteers) post-vaccination in the low and mid dose
groups respectively. Among positive responders, the
median magnitude across visits ranged from 0.09% to
0.23% in the low dose group and from 0.06% to 0.17%
in the mid dose group.
Conclusion
This novel DC-targeted protein HIV vaccine in combina-
tion with poly ICLC is safe and immunogenic in humans.
Cellular and humoral immune responses are induced.
Antibody responses are durable, with antibody titers
unchanged at 6 months following last immunization.
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